Price
$137.85-13.67%Social Signal Score
Analyst Ratings
13 analysts52-week range
- Last close
- $137.85
- Off 52w high
- -80.7%
- 200-day average
- $157.51
- vs 200-day
- -12.5%
Revenue
$3.00B+12.88%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian J. Choi
- Sector
- Industrials
- Industry
- Rental & Leasing Services
- Employees
- 21,000
- Beta
- 1.90
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 0.61
Financials
Revenue
$3.00B+12.9%Net Income
$35.00M-83.3%EBITDA
$229.00M-78.6%Free Cash Flow
$-3.72B-386.1%EPS (diluted)
$1.01-55.7%Shares Outstanding (diluted)
35.30M-61.5%Operating Expenses
$386.00MCash & Debt
$558.00MReturn of Capital
$0.00Revenue by Segment (annual)
$202.00MDividend per Share
$10.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $11.65B | $-889.00M | $-25.26 |
| 2024 | $11.79B | $-1.82B | $-51.23 |
| 2023 | $12.01B | $1.63B | $42.61 |
| 2022 | $11.99B | $2.76B | $58.44 |
| 2021 | $9.31B | $1.28B | $19.80 |
| 2020 | $5.40B | $-684.00M | $-9.70 |
| 2019 | $9.17B | $302.00M | $4.02 |
| 2018 | $9.12B | $165.00M | $2.08 |
| 2017 | $8.85B | $361.00M | $4.32 |
| 2016 | $8.66B | $163.00M | $1.78 |
| 2015 | $8.50B | $313.00M | $3.02 |
| 2014 | $8.48B | $245.00M | $2.32 |
| 2013 | $7.94B | $16.00M | $0.15 |
| 2012 | $7.36B | $290.00M | $2.72 |
Valuation
CARhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-62.50%Social Signal Score
Mentions (26)
- Newsprnewswire.com·23h ago·Neutral
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial First patient in current dose cohort exhibited no progression of her cancer three months aftertreatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct. 5, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the tr…
View source ↗ - Newszacks.com·4d ago·Positive
Can Higher Fleet Utilization Boost Avis Budget's Profitability? CAR's stronger utilization and lower fleet costs lift second-quarter profits despite fewer vehicles and softer rental volumes.
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma Annual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the launch of its inaugural Emerging Leadership & Innovation in Cell The…
View source ↗ - Newsprnewswire.com·4d ago·Neutral
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Following Lymphodepletion SAN JOSE, Calif., Oct. 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment …
View source ↗ - Newsglobenewswire.com·5d ago·Negative
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical trial underway at Roswell Park Treatment is designed to avoid pre-infusion chemotherapy and its side effects GB-5267 targets MUC16, a biomarker over-expressed in +80% of ovarian tumors BUFFA…
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
Portnoy Law Firm Announces Class Action on Behalf of Avis Budget Group, Inc. Investors LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Avis Budget Group, Inc., (“Avis” or the "Company") (NASDAQ: CAR) investors of a class action on behalf of investors that bought securities between February 20, 2025 - April 21, 2026, inclusive (the “Class Period”).
View source ↗ - Newsglobenewswire.com·12d ago·Negative
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million.
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Avis aux médias : Des policiers de la Saskatchewan seront honorés dans le cadre des Prix policiers de la famille Van de Vorst de MADD Canada pour leurs efforts visant à contrer la conduite avec capacités affaiblies OAKVILLE, Ontario, 17 sept. 2026 (GLOBE NEWSWIRE) -- MADD Canada invite les médias à assister à deux cérémonies spéciales en l'honneur des policiers de la Saskatchewan pour leurs efforts extraordinaires visant à mettre fin à la conduite avec capacités affaiblies, à assurer la sécurité
View source ↗ - Newsglobenewswire.com·20d ago·Positive
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that four abstracts from its off-the-s…
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform -Transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced clinical data from its off-the-shelf ant…
View source ↗ - Newsglobenewswire.com·27d ago·Negative
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent
View source ↗ - Newsgurufocus.com·35d ago·Negative
CAR Investors Have Opportunity to Lead Avis Budget Group, Inc. Securities Fraud Lawsuit Against Pentwater Capital Management LP CAR Investors Have Opportunity to Lead Avis Budget Group, Inc. Securities Fraud Lawsuit Against Pentwater Capital Management LP P
View source ↗ - News (RSS)investing·35d ago·Positive
Avis Budget Group stock analysis: technicals, key levels, and what’s driving Monday’s rally
View source ↗ - Newsseekingalpha.com·38d ago·Negative
Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way? Cema-cel produced MRD clearance in 58.3% of treated patients versus 16.7% under observation. The 97.7% median ctDNA reduction by day 45 shows substantial early biological activity. FDA RMAT and Fast Track designations support the development strategy but do not prove durable efficacy.
View source ↗ - Newszacks.com·42d ago·Positive
Here's Why Investors Should Hold Avis Budget in Their Portfolios Now CAR shares have jumped 57.8% in six months as rental demand, tech partnerships and buybacks support growth despite liquidity risks.
View source ↗ - Newsglobenewswire.com·43d ago·Neutral
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biotechnology company developing innovative cancer therapies, today announced that it has engaged Synex Consulting Ltd.
View source ↗ - 4chan /biz/biz·47d ago·Neutral
>>62609530 Is there an Avis rent a car general? I think GME was a psyop at this point.
View source ↗ - Newsseekingalpha.com·52d ago·Neutral
Adicet Bio: A Cheap Gamma Delta T-Cell Play Adicet Bio offers a differentiated allogeneic gamma delta CAR-T platform targeting autoimmune diseases, trading below cash value with a pivotal readout imminent. Early prula-cel data in lupus nephritis showed 50% complete renal response and clean safety, supporting the curative CAR-T thesis versus chronic biologics. The upcoming 3Q 2026 readout on 22 patients is a binary catalyst; durability and long-term remission are critical for upside realization.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
…s Founder, Chief Executive Officer (“CEO”), and Chief Investment Officer Matthew Halbower (“Halbower”) and on behalf of investors in Avis Budget Group, Inc. (NASDAQ: CAR). This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Avis securities between February 20, 2025 and April 21, 2026, both dates inclusive (the “Class Period”).
View source ↗ - News (RSS)bbc·53d ago·Positive
French ambassador to CAR accused of misconduct at official residence faces disciplinary action The accusations against Bruno Foucher prompted investigations into a potential security breach.
View source ↗ - Newsprnewswire.com·59d ago·Negative
RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias /PRNewswire/ -- RiboX Therapeutics Ltd. ("RiboX"), a global clinical-stage biotechnology company pioneering fully engineered circular RNA (circRNA)
View source ↗ - 4chan /biz/biz·59d ago·Neutral
>>62572824 >he doesn't know about CAR
View source ↗ - 4chan /biz/biz·59d ago·Positive
>>62571966 >HTZ will probably end the day at $3 why not go higher the volume looks ripe for a crazy run up like CAR
View source ↗ - 4chan /biz/biz·60d ago·Positive
>>62571508 or it could squeeze like CAR earlier this year it's a gamble
View source ↗
Earnings
Mon, Oct 26(in 3 weeks)
Consensus estimate $8.22 per share
Typical surprise -52.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$0.98 vs $2.05miss
- Wed, Apr 29$-8.01 vs $-6.82miss
- Wed, Feb 18$-6.53 vs $-0.29miss
- Mon, Oct 27$10.11 vs $8.11beat
- Tue, Jul 29$0.10 vs $2.02miss
- Wed, May 7$-14.35 vs $-5.95miss
Estimates and results for CAR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CAR officers and directors.
- Bought
- —
- Sold
- $489.7m
0 trades
91 trades
- Simhambhatla Ravisold
- Simhambhatla Ravisold
- Simhambhatla Ravisold
- Simhambhatla Ravisold
- Linnen Edward Psold
- Linnen Edward Psold
- Pentwater Capital Management Lpsold
- Pentwater Capital Management Lpsold
9 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.